Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $12.00 → $4.00 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $10.00 | Buy | HC Wainwright & Co. |
| 8/11/2021 | $33.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503
Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00
-- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into
Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously
HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00
Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical
BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia. “We are exc
SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503
Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co
SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)